Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
Dhargam Aljebouri, Laboratory Director at Clinical Immunology, Allergy and Transfusion Medicine – Specialized Immunosciences Laboratory, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Transfusion, adding:
“Proud to share that our case report (First molecularly characterized Para-Bombay phenotype in Iraq: Clinical, serological and genetic insights with implications for transfusion safety), has now been published in Transfusion (The Journal of AABB).
This represents the first molecularly characterized Para-Bombay phenotype reported from Iraq and, to the best of my knowledge, the first published molecularly characterized Para-Bombay case from the Arab world.
This work highlights the value of integrating advanced immunohematology, secretor studies and molecular characterization of FUT1/FUT2 to improve recognition of H-deficient phenotypes and transfusion safety.
My sincere thanks to all co-authors for their valuable contributions and collaboration throughout this work, with special appreciation to the team of the Specialized Immunosciences Laboratory, Al-Moayed Medical Network for their dedicated technical support and laboratory efforts.
I dedicate this publication to the memory of my beloved sister, Zahraa.
A meaningful contribution to rare blood group science and transfusion medicine from Iraq.”
Title: First molecularly characterized Para-Bombay phenotype in Iraq: Clinical, serological and genetic insights with implications for transfusion safety
Authors: Dhargam Muhamed Aljebouri, Mohammed Aljadiri, Bassam Alshaikhli, Rawa Alattabi, Arwa Alkhamess, Sajjad Aldoori, Yousif Suleiman
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia
-
Sep 8, 2026, 15:23Marissa Lechuga: Digital Transformation in Healthcare for People Living With SCD
-
Sep 8, 2026, 15:21Mohammed Javad Yousefi: Iron Deficiency and Anaemia Among Adolescent Girls in Iran
-
Sep 8, 2026, 15:21ISTH 2026 Highlights, Expert Insights Into Thrombosis and Hemostasis – RFHT
-
Sep 8, 2026, 15:20Eric Topol: Anti-H2B Autoantibodies Linked to Aortic Calcification in Atherosclerosis
-
Sep 8, 2026, 15:20David Walcott: The History of SCD Scientific Progress and Patient Advocacy
-
Sep 8, 2026, 15:19Nilesh Jethwa: Reported Adverse Events and Safety Signals With Ofatumumab